Does Adding a Second Drug to Your Statin Prevent More Heart Attacks? What the Trials Show

Adding a second cholesterol drug on top of a statin does prevent heart attacks and strokes in high-risk patients, and the benefit scales with how far the LDL cholesterol falls. Two large randomized trials, IMPROVE-IT and FOURIER, tested that idea from opposite ends: one added a mild pill, the other added a powerful injection. Read together, they turn a plausible theory into settled evidence.

Key points#

• A statin is usually the first drug, but it is not the only tool. Ezetimibe and PCSK9 inhibitors lower LDL through different mechanisms.
• IMPROVE-IT showed a small LDL drop from ezetimibe bought a small, real reduction in events.
• FOURIER showed a large LDL drop from the PCSK9 inhibitor evolocumab cut major events by about 15 percent.
• Both trials studied high-risk patients, so the results should not be stretched to everyone.
• Neither trial reduced deaths within its follow-up window. The gains were in nonfatal events.

The question these trials were built to answer#

For years, cholesterol treatment leaned almost entirely on statins because they were the only LDL-lowering drugs with strong outcome data behind them. That created a genuine uncertainty. Suppose a statin brings your LDL down but your cardiovascular risk stays high. If you add a second drug that lowers LDL further by a completely different route, do they actually suffer fewer heart attacks and strokes, or does the extra number on the lab report change nothing that matters?

That distinction is the whole point. A lower LDL value is a surrogate. What you care about is a longer, healthier life. IMPROVE-IT and FOURIER were designed to find out whether pushing LDL below what a statin alone reaches pays off in events you can feel, not just in a better lab slip. Separating an intermediate measurement from a real outcome is a core habit of careful evidence appraisal, and it is exactly the lens these two trials reward.

The gentle add-on: IMPROVE-IT#

IMPROVE-IT, reported in the New England Journal of Medicine in 2015, enrolled 18,144 patients who had recently been hospitalized for an acute coronary syndrome. Everyone took the statin simvastatin. On top of it, half received ezetimibe, a pill that blocks cholesterol absorption in the intestine, and half received a placebo.

The gap in LDL between the two groups was small. Averaged over the study, LDL sat around 54 mg/dL with ezetimibe versus about 70 mg/dL without it, a difference of roughly 16 mg/dL. After a median of about six years, the combined endpoint of cardiovascular death, major coronary events, and stroke happened in 32.7 percent of the ezetimibe group and 34.7 percent of the statin-only group. That is about a 2 percentage point absolute difference, a hazard ratio of 0.94, and a p-value of 0.016.

Two features of that result are worth sitting with. The effect really is modest: many patients would need to be treated for years to prevent a single event, and the statistical result lands close to the boundary of no benefit. Yet the trial mattered far beyond its size, because it was the first to show that a non-statin LDL-lowering drug added to a statin reduces events. That pointed the credit at LDL lowering itself rather than at some special property of statins. A small drop in LDL bought a small drop in risk, roughly in proportion.

The powerful add-on: FOURIER#

FOURIER, published in the same journal in 2017, tested a much stronger tool. It enrolled 27,564 patients who already had atherosclerotic cardiovascular disease and whose LDL stayed at 70 mg/dL or higher despite statin therapy. On top of the statin, patients received either evolocumab, an injected antibody that blocks the PCSK9 protein and prompts the liver to clear far more LDL from the blood, or a placebo.

Here the LDL change was dramatic. Evolocumab cut LDL by about 59 percent, from a median near 92 mg/dL down to roughly 30 mg/dL, well beneath the floor statins reach on their own. Over a median follow-up of about 2.2 years, the primary combined endpoint dropped with a hazard ratio of 0.85, a 15 percent relative reduction. The tighter secondary endpoint of cardiovascular death, heart attack, or stroke fell further, to a hazard ratio of 0.80.

A caveat keeps the picture honest. FOURIER did not reduce cardiovascular death or death from any cause during its follow-up. The benefit came from fewer heart attacks, strokes, and procedures to reopen arteries. On the safety side, the trial found no rise in new diabetes or in memory and thinking problems over its duration, easing two worries about very low LDL, though the follow-up was short for questions that unfold across decades.

Putting the two trials side by side#

Line them up and they tell one consistent story. A small LDL reduction produced a small reduction in events. A large LDL reduction produced a larger one. The link between how far LDL falls and how much risk falls runs close to a straight line, and it holds well below the levels statins alone achieve. This is among the firmest practical arguments that LDL is a cause of atherosclerosis rather than a bystander that merely travels alongside it.

A few qualifiers stop this from becoming a blanket case for stacking drugs on everyone. Both trials enrolled high-risk people: a recent acute coronary syndrome in IMPROVE-IT, established vascular disease in FOURIER. Those findings do not automatically carry over to lower-risk primary prevention, where the absolute payoff would be smaller. A relative reduction of 15 to 20 percent can sound large while the benefit to any one person over a few years stays modest. And neither add-on lowered mortality inside its trial window. The clearest value of these drugs is preventing nonfatal events in people whose baseline risk is already high, where a percentage cut translates into a meaningful count of heart attacks and strokes avoided.

The bottom line#

What the evidence establishes is narrower and steadier than any single product's marketing. Lowering LDL further, on top of a statin, prevents cardiovascular events in high-risk patients, and the size of that benefit rises with the size of the LDL reduction. IMPROVE-IT proved the principle with a gentle drug and a small effect. FOURIER confirmed it with a powerful one and a larger effect. The judgment for any individual, weighing absolute benefit against cost and burden, still belongs in the exam room.